REDHILL BIOPHAR/S (NASDAQ:RDHL) Rating Increased to Strong-Buy at WBB Securities

Share on StockTwits

REDHILL BIOPHAR/S (NASDAQ:RDHL) was upgraded by analysts at WBB Securities from a “buy” rating to a “strong-buy” rating in a research report issued on Friday, Marketbeat reports. The firm presently has a $17.00 price objective on the biotechnology company’s stock. WBB Securities’ price objective would suggest a potential upside of 129.73% from the company’s current price.

A number of other equities analysts have also recently issued reports on the stock. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Zacks Investment Research cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. Finally, Ascendiant Capital Markets set a $23.00 price target on shares of REDHILL BIOPHAR/S and gave the stock a “buy” rating in a research note on Monday, July 8th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $17.75.

Shares of REDHILL BIOPHAR/S stock opened at $7.40 on Friday. The company has a market cap of $145.66 million, a PE ratio of -4.35 and a beta of 1.40. The stock has a 50-day moving average price of $7.05. REDHILL BIOPHAR/S has a 1 year low of $5.13 and a 1 year high of $11.49. The company has a current ratio of 4.09, a quick ratio of 3.99 and a debt-to-equity ratio of 0.06.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.04. The company had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.98 million. REDHILL BIOPHAR/S had a negative net margin of 506.47% and a negative return on equity of 97.62%. Research analysts anticipate that REDHILL BIOPHAR/S will post -1.3 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Van ECK Associates Corp boosted its stake in REDHILL BIOPHAR/S by 42.1% in the 4th quarter. Van ECK Associates Corp now owns 10,787 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 3,195 shares in the last quarter. Geode Capital Management LLC bought a new position in REDHILL BIOPHAR/S during the 4th quarter valued at about $73,000. D. E. Shaw & Co. Inc. bought a new position in REDHILL BIOPHAR/S during the 4th quarter valued at about $186,000. Sanders Morris Harris LLC bought a new position in REDHILL BIOPHAR/S during the 2nd quarter valued at about $330,000. Finally, Menta Capital LLC lifted its stake in REDHILL BIOPHAR/S by 9.4% during the 4th quarter. Menta Capital LLC now owns 93,872 shares of the biotechnology company’s stock valued at $521,000 after acquiring an additional 8,087 shares during the period. Institutional investors own 35.48% of the company’s stock.

About REDHILL BIOPHAR/S

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Read More: Google Finance Portfolio

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.